Together, our findings establish a senescence-driven PAK4/AKT signaling circuit that fosters an aggressive, immunomodulatory endometriosis subtype and identify stigmasterol as a promising senescence-targeted therapeutic agent. This evidence concerns the gene AKT1 and endometriosis.